Scienture Holdings Inc. (NASDAQ:SCNX) announced that it has signed several Group Purchasing Organization (GPO) agreements covering its REZENOPY (naloxone HCl) Nasal Spray 10 mg, according to a company press release.
Through these agreements, the product will gain access to more than 5,000 healthcare institutions across the United States. These include hospitals, clinics, nursing homes, emergency medical services providers, first responders and rehabilitation centers. The company said the arrangements could enable REZENOPY to reach roughly 60% of the U.S. institutional healthcare market.
REZENOPY is a 10 mg naloxone nasal spray approved by the U.S. Food and Drug Administration on April 19, 2024, for the emergency treatment of known or suspected opioid overdoses in both adult and pediatric patients. The product is packaged in cartons containing two single-use intranasal spray devices.
According to market data from IQVIA cited by the company, the U.S. naloxone market generated approximately $141 million in annual sales as of January 2026, with about 9.4 million prescription units dispensed.
The commercial expansion comes as Scienture faces ongoing financial challenges. The company’s shares currently trade around $0.39, close to a 52-week low of $0.37, and have declined roughly 69% over the past year. Despite reporting revenue growth of 208% over the last twelve months, the company remains unprofitable with a loss per share of $1.57 and maintains a market capitalization of about $15.8 million.
“These GPO agreements represent a significant step forward in the commercial expansion of REZENOPY,” said Narasimhan Mani.
Scienture noted that its gross profit margins currently stand at approximately 88%, and analysts expect sales growth during the current year.
The company’s subsidiary Scienture LLC obtained exclusive U.S. commercialization rights for REZENOPY in March 2025 through an agreement with Summit Biosciences Inc., a subsidiary of Kindeva Drug Delivery L.P..
REZENOPY is contraindicated in patients with known hypersensitivity to naloxone hydrochloride. Safety warnings include risks such as recurrent respiratory depression, limited effectiveness with certain opioid types, severe opioid withdrawal symptoms and potential cardiovascular effects. Clinical studies have reported adverse reactions including upper abdominal pain, nasopharyngitis and dysgeusia.
Scienture operates primarily through Scienture LLC and focuses on developing and commercializing specialty pharmaceutical products.
In other recent developments, Scienture announced expanded access for its liquid losartan product ARBLI after securing multiple pharmacy benefit manager rebate agreements and institutional GPO contracts. The expansion provides access to more than 2,500 healthcare facilities and covers over 100 million patients through major national health plans.
The company also confirmed plans to launch REZENOPY commercially in the second quarter of 2026, with distribution to wholesale channels expected to begin in the first quarter of the same year.
Separately, the United States Patent and Trademark Office granted a patent covering the REZENOPY nasal spray formulation, providing intellectual property protection until February 2041. The patent was issued to Summit Biosciences, the Kindeva subsidiary that developed the product.
REZENOPY, approved by the FDA in April 2024, is described as the highest-strength naloxone nasal spray currently available for emergency treatment of suspected opioid overdoses.